# A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

> **NCT03929666** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 74 (actual)

## Conditions studied

- HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

## Interventions

- **DRUG:** ZW25 (Zanidatamab)
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03929666
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-29
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929666, "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03929666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*